No Data
No Data
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Market Whales and Their Recent Bets on BMY Options
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
No Data
RDK79 : Sorry, what’s a pdufa?